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Interleukin (IL)-10 is known to be an autoregulatory factor of functions of monocyte macrophages. The purpose of 
this study was to determine whether IL-10 production by alveolar macrophages (AMs) is altered in patients with 
lung cancer. AMs were obtained by bronchoalveolar lavage from 25 patients with lung cancer and 14 control 
patients. The production of IL-10 by AMs was quantitated by enzyme immunoassay with or without stimulation 
with lipopolysaccharide (LPS). No significant difference in spontaneous and LPS-stimulated IL-10 production by 
AMs was observed between lung cancer patients and control patients (mean i SEM; 288.0 _+ 56.7 vs. 249.6 + 58.4 pg 
ml-‘). IL-10 production of LPS-stimulated AMs was not impaired even in lung cancer patients with systemic 
metastasis. IL-4 failed to suppress LPS-induced production of IL-10 by AMs both in control patients and in lung 
cancer patients. In eight patients with lung cancer, IL-10 production by AMs was estimated before and after 
systemic chemotherapy and IL-10 production by LPS-stimulated AMs tended to increase after systemic 
chemotherapy from 152.3 +_ 51.9 to 278,Oi 112.8 pg ml-‘. As IL-10 is a potent inhibitor of tumour angiogenesis, 
an important process of tumour progression, these results suggest that, even in advanced cancer patients, 
macrophages can produce potent angiogenesis inhibitor and systemic chemotherapy may augment this inhibitory 
activity in the lung. 
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Introduction 
Angiogenesis is a multistep process involving degradation 
of extracellular matrix proteins and activation, prolifera- 
tion and migration of endothelial cells. Although normal 
angiogenesis is strictly regulated and self-limiting, recent 
investigations have revealed that pathological angiogenesis 
contributes to various disease status, including tumour 
progression (1,2). Several soluble factors have been 
identified that have angiogenic activity and in several 
turnours, macrophages, as well as tumour cells, are 
considered to be a source of these angiogenic molecules 
(3-5). 
It is well known that functions of monocyte macrophages 
are regulated through various mechanisms and, among 
those factors, interleukin (IL)-10 is known as an auto- 
regulatory factor which is produced by monocyte macro- 
phages (6). As IL-10 suppresses production of angiogenic 
molecules and, moreover, augments production of angio- 
genesis inhibitor by activated macrophages (7,8), it is of 
interest to examine the ability of monocyte macrophages to 
produce endogenous IL-IO in the tumour-bearing state. 
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Although various previous studies have revealed that 
various functions of monocyte macrophages, such as 
chemotactic activity, antibody-dependent cell-mediated 
cytotoxicity and cytostatic activity, are impaired in cancer 
patients (9-l l), no information is yet available on the 
ability of monocyte macrophages to produce IL-IO in 
cancer patients. 
In the present study, we examined production of IL-IO 
by alveolar macrophages (AMs), which are major effector 
cells in inflammatory and/or immune responses in the lung 
(9-12), in lung cancer patients in comparison with those in 
control patients and the influence of systemic chemotherapy 
was also examined. 
Materials and Methods 
PATIENTS WITH LUNG CANCER 
Twenty-five patients (22 smokers and three non-smokers) 
with primary lung cancer were studied after obtaining 
informed consent. Their mean age was 69.3 years (range 
57-79 years). They had not received any conventional 
anticancer therapy before the study. Lung cancer was 
diagnosed by either histological examination of tissue 
specimens or cytological examination of sputum, or speci- 
mens obtained by bronchial brushing, lymph-node biopsy 
or lung aspiration. On histological examination, the 
tumours were identified as five small-cell lung cancers 
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(SCLCs) (mean age 68.2 years, range 57-74 years) and 20 
non-small-cell lung cancers (NSCLC) (mean age 69.6 years, 
range 59-79 years) (adenocarcinoma in 10 cases, squamous 
cell carcinoma in eight cases, large-cell carcinoma in 
one case and adenosquamous cell carcinoma in one case). 
The stage of lung cancer was graded according to the 
tumour-node-metastasis classification system (Union In- 
ternationale Contre le Cancer, 1987). Clinical staging was 
determined according to the criteria of the Japanese Lung 
Cancer Association. The stage classification was as follows: 
SCLC (stage IIIB, 2; stage IV, 3); adenocarcinoma (stage I, 
1; stage II, 1; stage IV, 8); squamous cell carcinoma (stage 
IIIA, 2; stage IIIB, 4; stage IV, 2); large cell carcinoma 
(Stage IV, 1) and adenosquamous carcinoma (Stage IV, 1). 
Eight of the patients (three with SCLC, three with 
adenocarcinoma, two with squamous cell carcinoma) 
received a second examination with a bronchofibrescope 
about 10 weeks later, after two cycles of chemotherapy. 
Two patients received cisplatin-based chemotherapy and 
the other six patients received carboplatin-based chemo- 
therapy. The therapeutic responses were evaluated at the 
same time: partial response (SCLC, 3; squamous cell 
carcinoma, 2; adenocarcinoma, l), no change (adenocarci- 
noma, 1) and progressive disease (adenocarcinoma, 1). No 
complication of atopic diseases was observed in these lung- 
cancer patients. 
CONTROL PATIENTS 
Fourteen control subjects (seven smokers and seven non- 
smokers) were studied: nine men and five women aged 
25-73 (mean 52.8 years). The objective of bronchofibre- 
scopy was further examination of chronic cough in one 
patient, of recent small haemoptysis in six patients and of 
chest radiographical opacities in seven patients. In each 
case, no malignant lesion was found on examination with 
the bronchofibrescope. No complication of atopic diseases 
was observed in these control patients. 
REAGENTS 
RPM1 1640 medium (Nissui Pharmaceutical Co., Tokyo, 
Japan) supplemented with glutamine (1 mM) and gentami- 
tin (50 ug ml-‘) was used in all experiments. Recombinant 
human IL-4 (lot 801; specific activity, 1.0 x lo6 U mg 
protein-‘) was a kind gift from Ono Pharmaceutical Co. 
(Osaka, Japan). None of these reagents contained endotox- 
ins as judged by Limulus amoebocyte assay (Seikagaku 
Kogyo Co., Tokyo, Japan) in which the minimum detection 
level is 0.1 ng ml-‘. Lipopolysaccharide (LPS) derived 
from Escherichia coli 055:B5 strain was purchased from 
Difco Laboratory (Detroit, MI, U.S.A.). 
PREPARATION OF HUMAN ALVEOLAR 
MACROPHAGES 
AMs were obtained by bronchoalveolar lavage (BAL) 
after obtaining informed consent as described in detail 
previously (13). For BAL, the oral cavity and the upper 
airway were anaesthetized with lidocaine spray, and the 
tip of an Olympus fibre-optic bronchoscope (Model BF- 
lT20; Olympus Co., Tokyo, Japan) was wedged into one 
segment of the lung. Endobronchial findings in all control 
patients were normal and in this group the right middle 
lobe or lingular segment was lavaged. In the cancer group, 
BAL was performed in the non-tumour-bearing subseg- 
ment of the middle lobe or lingular segment at the 
diagnostic fibre-optic bronchoscopy. The lung was washed 
with 50 ml of sterilized saline (0.9%) prewarmed to 37°C 
and the fluid was gently sucked out with a 50 ml syringe. 
This process was repeated three times. A total of 150 ml of 
saline was instilled, of which about 40-70% was recov- 
ered. Immediately after collection, an aliquot was reserved 
for cytocentrifugation and staining (Diff-Quick method, 
American Scientific products, McGaw Park, IL, U.S.A.) 
for cell differential analysis. The remainder of the cells 
were counted, washed twice, and suspended in serum-free 
RPM1 1640 medium. There was no difference in total BAL 
cell number or percentage of AMs in BAL cells between 
lung cancer patients and control patients (1.15 + 0.12 vs 
1.28 + 0.18 x 10’ cells; 96.510.34 vs. 95.61 0.43 %). The- 
viability of AMs was over 90%, as assessed by the trypan 
blue dye exclusion test. Cells were plated in each well of 
96-well, flat-bottomed culture plates (Falcon 3072, Becton 
Dickinson, Lincoln Park, NJ, U.S.A.) at a concentration 
of 5 x lo4 AMs per well, incubated for 1 h at 37°C under 
5% CO2 in air and then washed twice with warm medium 
to remove non-adherent cells. At this point, over 99% of 
the adherent cells in monolayers were macrophages, as 
judged by morphological examination and non-specific 
esterase staining. 
IN VITRO ACTIVATION OF AMs 
AMs were incubated in RPM1 1640 medium containing 
10% heat-inactivated fetal bovine serum (FBS) (GIBCO, 
Grand Island, NY, U.S.A.) with or without LPS (1 ug 
ml-‘) in the presence or absence of IL-4 (100 U ml-‘) for 
18 h at 37°C under 5% COz in air. LPS at lug ml-’ was 
chosen to examine the potency of AMs to produce 
cytokines, and IL-4 at 100 U ml-’ was chosen as a optimal 
concentration for suppression of cytokine production by 
monocyte macrophages (14,lS). The cell-free supernatants 
were harvested and kept in a freezer for measurement of 
cytokine secretion. 
MEASUREMENTS OF IL-10 AND IL-lf3 BY 
ENZYME IMMUNOASSAY 
The supernatants of the AMs culture were pooled and 
protein concentrations of IL-10 and IL-lb were measured 
quantitatively by enzyme immunoassay (EIA). EIAs for 
human IL-10 and IL-ID were performed essentially as 
described previously (13-15). The sensitivity limits of the 
EIAs for IL-10 and IL-l/3 were 20 pg ml-‘. 
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STATISTICAL ANALYSIS 
Results are expressed as mean -+_ SEM. The statistical 
significance of differences between test groups was analysed 
by the Mann-Whitney U-test. Probability values of less 
than 0,05 were considered statistically significant. 
Results 
IL-10 PRODUCTION BY AMs FROM 
LUNG-CANCER PATIENTS AND CONTROL 
PATIENTS 
We compared IL-10 production by AMs from lung-cancer 
patients with that from control patients. Samples of AMs 
from 14 control patients and 25 lung cancer patients were 
incubated with or without LPS (1 pg ml-‘) for 18 h. Then, 
IL-10 in the culture supernatants was quantitated by EIA. 
AMs from two out of 14 control patients produced low 
levels of IL-10 (39 pg ml-’ and 63 pg ml-‘) spontaneously. 
AMs from other control patients and from none of the 
lung-cancer patients produced IL-10 spontaneously. There 
was no difference between LPS-induced production of IL- 
10 by AMs from lung-cancer patients and from control 
patients (Fig. 1) (288.0+ 56.7 vs. 249.6k58.4 pg ml-‘). 
LPS-induced production of IL-10 by AMs from smokers 
with lung cancer (294.0& 61.7 pg/ml-‘) was similar to that 
from control smokers (229.0 I86.1 pg ml-l). LPS-induced 
production of IL-10 by AMs from non-smokers with lung 
cancer (241 .O i 165.0 pg ml-‘) was also similar to that from 
control non-smokers (270.0_+ 84.8 pg ml-‘). 
IL-10 PRODUCTION BY AMs FROM 
LUNG-CANCER PATIENTS WITH 
DIFFERENT HISTOLOGICAL FEATURES 
AND AT DIFFERENT CLINICAL STAGES 
We compared IL-10 production by AMs from patients with 
different histological types of lung cancer. As SCLC is 
reported to impair immune functions (16,17), the patients 
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FIG. 1. IL-10 production by alveolar macrophages from 
lung-cancer patients and control patients. Large symbols 
and bars show means with SEMS for each group. 0, 
Smokers; 0, non-smokers; NS, not significant. 
were divided into two groups; SCLC and NSCLC. As 
shown in Table 1, there was no difference in the production 
of IL-10 by AMs between the SCLC group and the NSCLC 
group. 
Next, we compared the IL-IO production by AMs from 
lung-cancer patients with or without clinical distant 
metastasis. Results are also shown in Table 1. There was 
no difference between the production of IL-10 by AMs in 
patients without clinical distant metastasis (Stage 1-IIIB) 
and in patients with clinical distant metastasis (Stage IV) 
EFFECT OF IL-4 ON IL-10 PRODUCTION OF 
AMs FROM LUNG-CANCER PATIENTS 
We have already reported that IL-4 suppresses pro- 
inflammatory cytokine production by human AMs 
(14,15). In the present study, we compared the effect of 
IL-4 on IL-10 production by AMs with its effect on IL-lb 
production by AMs from lung-cancer patients and from 
control patients. For this, samples of AMs from six control 
patients and eight lung cancer patients were incubated with 
or without LPS (1 pg ml-l) for 18 h in the presence or 
absence of 100 U ml-’ of IL-4. Then, IL-10 levels in the 
culture supernatants were quantitated by EIA. Among the 
control and lung cancer patients, AMs produced low levels 
of IL-10 only in one case, and IL-4 alone had only a 
marginal effect on the spontaneous production of IL-10 
(increase from 39 pg ml to 45 pg ml-l). LPS-induced 
production of IL-l/l by AMs was suppressed by IL-4 both 
in the control patients and lung-cancer patients and the 
difference was statistically significant in lung-cancer pa- 
tients (P = 0.027) (Fig. 2). In these experimental conditions, 
IL-4 had failed to suppress LPS-induced production of IL- 
10 by AMs from lung-cancer patients or from control 
patients (Fig. 2). 
INFLUENCE OF SYSTEMIC 
CHEMOTHERAPY ON IL-10 PRODUCTION 
OF AMs FROM LUNG-CANCER PATIENTS 
Finally, the production of IL-10 by AMs from eight lung 
cancer patients before and after platinum-containing 
chemotherapy were compared as follows. Samples of 
AMs were incubated in medium with or without LPS 
(1 pg ml-‘) for 18 h and then the culture supernatants were 
harvested and IL-10 was quantitated by EIA. Results are 
shown in Fig. 3. IL-10 was undetectable in unstimulated 
AMs supernatants in the group before or after chemother- 
apy. After stimulation with LPS, mean IL-10 secretion 
from AMs in the group after chemotherapy (278.0 + 112.8 
pg ml-‘) was higher than that in the group before 
chemotherapy (152.3 k 51.9 pg ml- ‘), but the range of 
values was large and the difference was not statistically 
significant. Within the limit of the six patients who had 
responded to systemic chemotherapy, the mean IL-10 level 
excreted by LPS-stimulated AMs after chemotherapy 
(299.5_+ 145.0 pg ml-‘) was also higher than that before 
chemotherapy (177.7 t- 67.2 pg ml-‘), but the difference did 
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TABLE 1. LPS-induced production of IL-10 by AMs from lung-cancer patients with different histological features and at 
different clinical stages 
LPS-induced production of IL-10 (pg ml-‘) 
Histology 
Small-cell lung cancer (n=5) 
Non-small-cell lung cancer (n=ZO) 
Clinical stage 
Stage I-IIIB(n= 10) 
Stage IV(n= IS) 
300.2 f 113.7 NS 
284.9 5 66.4 I 
258.3 _+ 70.6 NS 
307.7+ 83.6 I 
LPS, lipopolysaccharide; NS, not significant. 
not reach statistical significance. In the SCLC responder 
group, on in vitro treatment with LPS, IL-10 production by 
AMs obtained after chemotherapy (550.0 + 205.6 pg ml-‘) 
was also higher than that by AMs obtained before 
chemotherapy (208.3 & 133.9 pg ml-‘). In non-responders 
to systemic chemotherapy, LPS-induced IL-10 production 
by AMs decreased (from 74 pg ml to 25 pg ml-‘) in one 
patient and increased (from 78 to 402 pg ml-‘) in another 
upon systemic chemotherapy. 
Discussion 
In the present study, we observed that AMs from lung- 
cancer patients produce similar amounts of IL-10 upon 
stimulation with LPS to those produced by control patients 
and this is the first demonstration of the ability of monocyte 
macrophages to produce IL-10 in cancer patients. More- 
over, LPS-induced production of IL-IO by AMs tended to 
increase upon systemic chemotherapy. 
There are various reports on the functional changes of 
AMs in patients with lung cancer, such as a decrease in 
chemotactic activity, antibody-dependent cell-mediated 
cytotoxicity and cytostatic activity (9-11). On the other 
P < 0.05 
Control patients Lung-cancer patients 
(n=6) (n = 8) 
FIG. 2. Effect of IL-4 on the production of IL- 1 fl and IL- 
10 by AMs treated with lipopolysaccharide (0,LPS; a, 
LPS+IL-4). Data are given as mean+sEM. 
hand, we have already reported that AMs in lung-cancer 
patients have a similar ability to produce cytokines, such as 
tumour necrosis factor-a, IL-lfl and the IL-1 receptor 
antagonist, to that of control subjects (18,19). To extend 
these previous findings, AMs from lung-cancer patients 
were found to have a similar ability to produce IL-10 to 
those of control patients (Fig. 1). 
Various studies have revealed that tumour-associated 
macrophages play important roles in tumour progression 
through the production of various soluble factors (3-5) 
and recent attention has been focused on the angiogenesis- 
related molecules produced by macrophages. Macro- 
phages produce various angiogenic cytokines, such as 
IL-l, IL-8, granulocyte-macrophage colony-stimulating 
factor, vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF), and proteases 
which degrade the extracellular matrix, such as metallo- 
proteinases and serine proteases (20,21). In addition, 
macrophages produce various angiogenic inhibitors. Tis- 
sue inhibitor of metalloproteinases (TIMPs) is a natural 
inhibitor produced by macrophages (22,23). In addition, 
IL-10 is known to inhibit angiogenic cytokine synthesis by 
human macrophages (6,24). Moreover, as IL-10 augments 
the production of TIMPs by macrophages (7), it can be 
q 400 - 
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Before After 
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FIG. 3. IL-10 production by alveolar macrophages from 
lung-cancer patients before and after systemic 
chemotherapy. Data are given as mean+sEM.n, All 
patients; q , responders to chemotherapy (n=6). 
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considered an autoregulatory factor of macrophage- 
mediated angiogenesis. In a nude mouse system, Huang 
et al. (8) reported that the transfection of IL-10 to 
melanoma cells resulted in significantly slower subcuta- 
neous tumour growing and fewer lung metastasis than 
control cells and considered suppression of macrophage- 
derived angiogenic factors by IL-10 as a possible mechan- 
ism of anti-tumour action. The present study revealed 
that, in lung-cancer patients, the ability of AMs to 
produce IL-10 is not impaired, even in advanced stage 
or SCLC patients (Table I). Therefore, augmentation of 
IL-10 production by macrophages in the tumour site could 
be a strategy to control tumour progression through the 
inhibition of angiogenesis. 
We have previously reported that IL-4 suppresses pro- 
inflammatory cytokine production by human AMs in 
normal subjects (14,1.5). To confirm and extend these 
previous findings, IL-4 suppressed IL-lp production by 
AMs not only from control patients, but also from lung 
cancer patients (Fig. 2). On the other hand, we have shown 
for the first time that IL-4 failed to suppress LPS-induced 
production of IL-IO by AMs from control or lung-cancer 
patients (Fig. 2). The reason for the difference in action of 
IL-4 on the production of IL-lp and IL-10 by AMs must be 
clarified in future studies, but it is of interest to speculate 
that IL-10 production is important as an autoregulatory 
mechanism of monocyte macrophage function and is 
resistant to modulation by other factors. 
Systemic chemotherapy is known to affect various 
functions of competent cells of the host immune system 
(17,25,26). The phagocytic oxidizing activity of AMs in 
SCLC patients was found to be suppressed during cytotoxic 
treatment (27). On the other hand, restoration of impaired 
functions of monocyte macrophages upon systemic che- 
motherapy has been reported (28,29) and a direct effect of 
chemotherapeutic agents on monocyte macrophages and 
decreased tumour burden upon chemotherapy are consid- 
ered to be possible mechanisms for the restoration. In the 
present study, IL- 10 production by AMs tended to increase 
upon systemic chemotherapy (Fig. 3) which suggests that 
the important role of IL-10 as an endogenous inhibitor 
of angiogenesis is still maintained after systemic chem- 
otherapy. 
Besides its role as an autoregulatory factor of monocyte 
macrophage function IL-10 is known to be a member of the 
Type 2 cytokines which suppress cellular immune responses 
(30,31) and a shift of the Type l/Type 2 balance towards 
Type 2 predominance has been reported in cancer patients 
(32-34). Previous studies have revealed that cancer cells 
produce IL-10 (35-37) and an increased expression of 
IL-10 by tumour-infiltrating lymphocytes has also been 
reported (38,39). Although Huang et al. (40,41) have 
reported that tumour-derived soluble factors induce IL- 10 
production by macrophages in vitro, and considered 
macrophages, in addition to tumour cells and lymphocytes, 
to contribute to the predominant Type 2 cytokine pattern, 
the present study did not confirm the overexpression of 
IL-10 by AMs in lung-cancer patients. 
In conclusion, we have demonstrated that macrophages 
have a potent ability to produce IL-IO in lung-cancer 
patients. Establishment of the protocol to apply this potent 
anti-angiogenic activity in cancer treatment is warranted. 
At the same time, further investigation is necessary 
to clarify whether macrophage-derived IL-10 has a role 
in the imbalance of Type l/Type 2 cytokines in cancer 
patients. 
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